Vera Therapeutics stock sinks following competitor’s successful trial
Investing.com -- Shares of Vera Therapeutics (NASDAQ:VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.